Curated News
By: NewsRamp Editorial Staff
September 03, 2025
BRAIN Biotech Appoints New EVP to Lead Enzyme Business Expansion
TLDR
- BRAIN Biotech AG appoints Johan Jansen-Storbacka to lead enzyme products, leveraging his 20 years of expertise to strengthen market position and drive business integration.
- Jansen-Storbacka will oversee 140 employees and manage fermentation facilities across the UK, Europe, and the US to integrate research and production activities.
- This leadership change supports BRAIN Biotech's mission to develop sustainable biological solutions for industries, contributing to more efficient and eco-friendly processes.
- Johan Jansen-Storbacka brings extensive experience in enzyme applications from industrial processes to home care, enhancing BRAIN Biotech's innovative capabilities.
Impact - Why it Matters
This leadership appointment signals BRAIN Biotech's strategic commitment to strengthening its position in the rapidly growing enzyme technology market, which has significant implications for multiple industries. Enzyme technology is increasingly critical for developing sustainable industrial processes, improving animal nutrition efficiency, and creating eco-friendly home care products. For consumers, this means potential advancements in more environmentally conscious products, while for industries, it represents continued innovation in biotechnological solutions that can reduce environmental impact and improve operational efficiency. The appointment of an experienced leader like Jansen-Storbacka suggests accelerated development and commercialization of enzyme-based solutions that could transform manufacturing processes across various sectors.
Summary
BRAIN Biotech AG, a leading German biotechnology company specializing in the biologization of industry, has appointed Johan Jansen-Storbacka as Executive Vice President of its BRAINBiocatalysts enzyme products business, effective September 1, 2025. Jansen-Storbacka brings over 20 years of extensive biotechnology experience, with expertise spanning industrial processes, animal nutrition, and home care applications. He holds both an M.Sc. in Engineering and Management and an MBA, making him exceptionally qualified to lead this critical division of the company.
Jansen-Storbacka succeeds Rod Sears-Black, who retired in January 2025, and will oversee approximately 140 employees while managing fermentation facilities in the UK and production sites across continental Europe and the United States. His appointment represents a strategic move by BRAIN Biotech to strengthen its enzyme and fermentation business while ensuring closer integration between research and production activities. CEO Adriaan Moelker, who temporarily held the role during the interim period, praised Jansen-Storbacka's broad industry background and international experience, noting his proven leadership skills make him an excellent fit for driving the company's enzyme products strategy forward.
The BRAIN Biotech Group, which generated €54.6 million in revenue in the 2023/24 fiscal year with approximately 300 employees, operates through two main business segments: BRAINBiocatalysts for enzyme development and distribution, and BRAINBioIncubator for research-intensive pharmaceutical projects. The company's focus on developing microbial production strains and scalable bioprocesses positions it at the forefront of creating more sustainable products and efficient industrial processes. For more information, readers can visit the original release on www.newmediawire.com to learn about this significant leadership appointment in the biotechnology sector.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, BRAIN Biotech Appoints New EVP to Lead Enzyme Business Expansion
